Page 22 - Cipla

Nifty to face stiff resistance at 9,500 levels: Gaurav Garg of CapitalVia

Technical Calls by Gaurav Garg, Head of Research at CapitalVia Global Research Limited- Investment Advisor

India gears up for patient trials on 20 different drugs for Covid-19

Local pharma units have already started work on developing patented drugs, some have already approached regulator for approvals

Cipla Health partners Swiggy, Zomato, Dunzo to deliver wellness products

Cipla Health will cater to 4 lakh people and cover 250 stores in 45 cities across the country

Coronavirus outbreak: Quick USFDA approvals for asthma drug makers

Cipla gets nod for drug from USFDA earlier than expected; Lupin in fray

Cipla surges 15% on USFDA nod for first generic Proventil HFA inhaler

Proventil HFA (albuterol sulfate) metered-dose inhaler is used for the treatment of acute episodes of bronchospasm or prevention of asthmatic symptoms.

Growth in domestic market likely to provide booster dose for pharma stocks

The pharma sector, once considered a safe bet, has been trailing the benchmark indices for four years in a row

Cipla surges 8% on completing Phase-3 study of asthma generic drug

Advair Diskus and its generic equivalents had US sales of approximately US$2.9bn for the 12-month period ending February 2020.

Top headlines: FM's relief package for poor, Cipla gets USFDA nod, and more

Business Standard brings to you the top headlines of the day

Pharma major Cipla gets USFDA nod for generic oral acid reflux drug

According to IQVIA, Nexium and its generic equivalents had US sales of around $70 million for the 12 months ended November 2019

Cipla down 8% in 5 days, nears 52-week low on warning letter for Goa plant

The Company said it remains committed to maintain the highest standards of compliance and will work closely with the agency to comprehensively address all the observations.

USFDA issues warning letter to Cipla for Goa manufacturing facility

The company further said that it remains committed to maintain highest standards of compliance and will work closely with the agency to comprehensively address all the observations

Cipla acquires 4 women's health brands from Wanbury to strengthen segment

Cipla said the nutraceutical products, to be sold under the four umbrella brands, would address various health needs for conditions arising due to nutritional deficiencies or insufficiencies

Cipla announces acquisition of nutrition products portfolio from Wanbury

The company has acquired 4 brands namely CPink, CDense, Productiv and Folinine to further strengthen its presence in women's health portfolio

Cipla sees opportunity for its anti-HIV drug as coronavirus toll nears 500

Doctors are scrambling for a potent treatment for the virus, which is spreading fast and has no vaccines available yet

Limited product launches, tepid sales in US dent Cipla's Dec quarter show

Niche product launches are key triggers for North American market

Cipla, Glenmark get NPPA nod for inhaler pricing over 'innovative' quotient

Glenmark had appealed to the pricing regulator in 2016 asking for a differential price for its Digihaler

Centre may cap trade margins for drugs in stages; companies oppose plans

While the trade margins for branded generics are standardised by trade, the margins vary in the case of unbranded generics

Cipla plans to partner Ayushman Bharat; start dialogue with insurance firms

There is a plan to identify a list of essential medicines, including antibiotics, painkillers, etc, which the company may supply to the Ayushman Bharat-empanelled hospitals.

Cipla acquires brand, trademark for anti-diabetic drug Vysov in India

Homegrown pharma major Cipla Ltd on Monday said it has acquired brand name and trademark rights for Vysov for anti-diabetic drug Vildagliptin for the Indian market from Novartis. However, it didn't disclose the acquisition amount. Cipla has been co-marketing Vildagliptin in agreement with Novartis under brand names Vysov and Vysov M (Vildagliptin plus Metformin), the company said in a regulatory filing. "Owing to the increased affordability of Vildagliptin it is more accessible for better management of the disease. Cipla's acquisition of the trademark rights of Vysov will enable us to contribute to easier access of the drug in India," Cipla Executive Vice-President & Head India Business Nikhil Chopra said. The products have witnessed a strong uptake in India for the last couple of years and are currently available across the country, the company said. Vildagliptin is backed by strong clinical data and is therefore a widely prescribed antidiabetic medicine for adults with type-2 ..

Domestic performance, steady growth outlook driving up Cipla stock

Promising domestic sales, new launches in the US are keeping analysts positive